FOLLICULAR LYMPHOMA

This early-stage study tests a new drug called IMT-009 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. About 67 participants will receive the drug intravenously,…

This study tests whether adding two drugs (tafasitamab and lenalidomide) to standard rituximab helps people with relapsed follicular or marginal zone lymphoma live longer without their cancer growing. About 654 adults who have already tried at least one prior treatment will be ra…

This study tests a new combination of drugs for people with a slow-growing lymphoma that has a high tumor burden. Participants receive a targeted pill (tazemetostat) along with two standard chemotherapy drugs, but with fewer cycles of one chemo to reduce side effects. The goal is…

This study tests a combination of two immunotherapy drugs, glofitamab and obinutuzumab, in 47 people with follicular lymphoma or marginal zone lymphoma who have not had prior treatment. The goal is to see how well the drugs control the cancer by measuring complete metabolic respo…

This study looked at how well and how safely the drug tazemetostat works in adults with a type of blood cancer called follicular lymphoma that has come back or not responded to previous treatments. Participants took tazemetostat pills twice daily. The study aimed to see if the dr…

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers or disorders. About 43 participants will receive vo…

This study tests a new drug, MK-2140, alone or with other treatments, in people with certain B-cell blood cancers that have come back or not responded to prior therapy. About 223 adults with mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, or Richter trans…

This study is for people with follicular lymphoma, a type of blood cancer, that has returned or no longer responds to treatment. It tests whether adding the drug tazemetostat to a standard two-drug combination can help patients live longer without their cancer getting worse. Abou…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing types of B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with various subtypes, including follicular lymphoma and chro…

This study tests a combination of two drugs, mosunetuzumab and polatuzumab vedotin, in people with untreated follicular lymphoma, a type of blood cancer. The drugs work together to help the immune system find and kill cancer cells. The main goal is to see how many patients have t…

This study tests an investigational drug called epcoritamab, given alone or with other standard treatments, in about 543 people with B-cell non-Hodgkin lymphoma. The goal is to find the best dose and see how well it shrinks tumors. Participants receive active treatment; no one ge…

This study aims to see how well the drug tazemetostat works in adults with a slow-growing blood cancer called follicular lymphoma that has come back or not responded to at least two prior treatments. Participants will take tazemetostat as prescribed by their doctor in routine car…

This study tests a combination of two drugs, tazemetostat (pills) and mosunetuzumab (injections), in people with untreated follicular lymphoma. The goal is to see if the combo works better than either drug alone while remaining safe. About 23 adults will take part, and the study …

This study tests whether combining two drugs—lenalidomide and epcoritamab—can better control follicular lymphoma that hasn't been treated yet. Follicular lymphoma is not curable, but this combination aims to boost the immune system to kill cancer cells more effectively. About 29 …

This study compares a shortened chemotherapy regimen combined with immunotherapy to the standard full-length treatment for people with newly diagnosed, advanced follicular lymphoma that has a high tumor burden. About 605 participants will be randomly assigned to either the shorte…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This early-phase study tests whether adding specially treated immune cells (called veto cells) from a donor can help stem cell transplants work better in people with blood cancers like leukemia or lymphoma. The goal is to help the donor cells grow without causing severe graft-ver…

This study tests a combination of two drugs, mosunetuzumab and lenalidomide, in people with follicular lymphoma, a type of blood cancer. The goal is to see if the combination is safe and effective, and to compare giving one drug as a shot under the skin versus through a vein. Abo…

This early-phase study looks at whether giving low-dose radiation before CAR T-cell therapy is practical and safe for people with B-cell lymphoma that has come back or not responded to treatment. About 33 adults will receive radiation to bridge them to a CAR T-cell infusion. The …

This study tests whether combining copanlisib and rituximab can slow or stop the growth of follicular lymphoma, a type of blood cancer. About 33 adults who have not yet been treated for their disease will receive the drugs through an IV over up to 13 cycles. The main goal is to s…

This study tests whether combining two drugs, obinutuzumab and CC-99282, can control follicular lymphoma that has a high tumor burden and has not been treated before. About 33 adults with stage II–IV disease will receive the combination and be monitored for side effects and respo…

This early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…

This study tests an experimental drug called epcoritamab in Japanese adults whose B-cell lymphoma has come back or not responded to treatment. The trial has two parts: first, finding a safe dose, and second, checking how well the drug works alone or with other treatments. About 7…

This early-phase study tests a personalized cancer vaccine made from each patient's unique tumor mutations. It is given along with pembrolizumab after standard rituximab treatment for follicular lymphoma. The goal is to see if this approach is feasible and can boost the immune sy…

This study looks at whether giving a pneumonia vaccine (PCV13) before and after CAR T-cell therapy can improve the immune system's ability to fight pneumococcus bacteria in people with certain types of lymphoma. About 26 participants with relapsed or hard-to-treat B-cell lymphoma…

This early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with Richter's transformation or certain non-Hodgkin lymphomas. The goal is to find the safest dose and see how well the drugs work together. About 27 adults will take part, and the study…

This study aims to create a model that combines clinical and genetic information to better predict which follicular lymphoma patients will remain cancer-free for at least two years after their first treatment. Researchers will analyze data from 370 patients to improve risk assess…